<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04178187</url>
  </required_header>
  <id_info>
    <org_study_id>444/23/07/2019</org_study_id>
    <nct_id>NCT04178187</nct_id>
  </id_info>
  <brief_title>The Role of Probiotics in the Eradication of Helicobacter Pylori</brief_title>
  <official_title>The Role of Probiotics in the Eradication of Helicobacter Pylori</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evangelismos Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Evangelismos Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients will receive quadruple eradication therapy for 10 days with Omerazole 20mg x2,
      Amoxicilin 1g x2, Clarithromycin 500mg x2 and Metronidazole 500mg x2. The patients will be
      randomised into two groups. The first group will receive one capsule of probiotics x2 two
      hours before or after meal for 15 days and the second group placebo (capsule with same
      composition and colour with probiotic) x2, two hours before or after meal for 15 days as
      well.

      The probiotic (Lactolevure, Uni-Pharma, Athens) contains four probiotic strains known for
      their effectivness and safety, Saccharomyces Boulandrii (1.5 BU/capsule), Bifidobacterium
      Lactis BB-12 (1.75 BU/capsule), Lactobacillus Acidodophilus LA-5 (1.75 BU/capsule) and
      Lactobacillus Plantarum (0.5 BU/capsule).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with H.Pylori infection establised after a uper GI endoscopy and gastric biopsy will
      receive quadruple eradication therapy for 10 days with Omerazole 20mg x2, Amoxicilin 1g x2,
      Clarithromycin 500mg x2 and Metronidazole 500mg x2. The patients will be randomised into two
      groups. The first group will receive one capsule of probiotics x2 two hours before or after
      meal for 15 days and the second group placebo (capsule with same composition and colour with
      probiotic) x2, two hours before or after meal for 15 days as well.

      The probiotic contains four probiotic strains known for their effectivness and safety,
      Saccharomyces Boulandrii (1.5 BU/capsule), Bifidobacterium Lactis BB-12 (1.75 BU/capsule),
      Lactobacillus Acidodophilus LA-5 (1.75 BU/capsule) and Lactobacillus Plantarum (0.5
      BU/capsule).

      Patients will report in a specific questionnare the presence or absence of symptoms
      suggestive of side effects associated with the Abx administered (i.e flatulance, abdominal
      pain, diarrhoea, regurgitation, vomiting).

      All patints will be subjected to urea breath test one month after the completion of treatment
      in order to verify HP eradication.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of antibiotic side effects</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Primary prevention of Abx side effects as assessed by a questionnaire including all possible side effects (i.e. vomiting, diarrhea, flatulence etc) on a ten point Likert scale.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Lactolevure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive quadruple eradication therapy for Helicobacter Pylori infection with Amoxicillin, Clarithromycin, Metronidazole, Omeprazole and Probiotics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive quadruple eradication therapy for Helicobacter Pylori infection with Amoxicillin, Clarithromycin, Metronidazole, Omeprazole and Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caps Lactolevure</intervention_name>
    <description>One group will receive Caps Lactolevure x2 and the other group Caps Placebo x2.</description>
    <arm_group_label>Lactolevure</arm_group_label>
    <other_name>Probiotics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caps Placebo</intervention_name>
    <description>Caps Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established Helicobacter Pylori Infection

        Exclusion Criteria:

          -  Pregnancy

          -  Lactate

          -  Previous eradication therapy for HP.

          -  Course of antibiotics and/or probiotics one month prior to stydy entry

          -  Course of PPI's, H2- antagonst and antacids two weeks prior to study entry

          -  Known allergy to antibiotics that will be used in study

          -  Coronary disease, heart failure,malignancy,thyroid disease, pulmonary disease or other
             serious disease as per medical judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikos Viazis, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Evangelismos Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katerina Kotzampassi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AHEPA University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olga Giouleme, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital Of Thessaloniki Ippokratio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Periklis Apostolopoulos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NIMTS Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sotirios Georgopoulos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iatriko Palaiou Falirou</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nikos Viazis, Dr</last_name>
    <phone>+302132041000</phone>
    <phone_ext>1609</phone_ext>
    <email>nikos.viazis@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christos Pontas, Dr</last_name>
    <phone>+302132041000</phone>
    <phone_ext>1273</phone_ext>
    <email>chrispontas@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Evangelismos Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikos Viazis, Dr</last_name>
      <phone>+302132041000</phone>
      <phone_ext>1609</phone_ext>
      <email>nikos.viazis@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Christos Pontas, Dr</last_name>
      <phone>+302132041000</phone>
      <phone_ext>1273</phone_ext>
      <email>chrispontas@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>NIMTS Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Periklis Apostolopoulos, MD</last_name>
      <phone>+30 2107288001</phone>
      <email>periklisapo@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Iatriko Palaiou Falirou</name>
      <address>
        <city>Palaió Fáliro</city>
        <zip>17562</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sotirios Georgopoulos,, MD</last_name>
      <phone>+30 2109892100</phone>
      <email>georgpap@ath.forthnet.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Thessaloniki AHEPA</name>
      <address>
        <city>Thessaloníki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katerina Kotzampassi, MD</last_name>
      <phone>+30 2313303110</phone>
      <email>kakothe@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaloniki Ippokratio</name>
      <address>
        <city>Thessaloníki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olga Giouleme, MD</last_name>
      <phone>+30 2313312000</phone>
      <email>olga.giouleme@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <results_reference>
    <citation>Kotzampassi K, Stavrou G, Damoraki G, Georgitsi M, Basdanis G, Tsaousi G, Giamarellos-Bourboulis EJ. A Four-Probiotics Regimen Reduces Postoperative Complications After Colorectal Surgery: A Randomized, Double-Blind, Placebo-Controlled Study. World J Surg. 2015 Nov;39(11):2776-83. doi: 10.1007/s00268-015-3071-z.</citation>
    <PMID>25894405</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 8, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Evangelismos Hospital</investigator_affiliation>
    <investigator_full_name>Nikos Viazis</investigator_full_name>
    <investigator_title>Consultant Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Helicobacter Pylori</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Eradication treatment of H.Pylori</keyword>
  <keyword>Antibiotics</keyword>
  <keyword>Proton pump inhibitors</keyword>
  <keyword>Saccharomyces boulardii</keyword>
  <keyword>Bifidobacterium lactis</keyword>
  <keyword>Lactobacillus acidophilus</keyword>
  <keyword>Lactobacillus plantarum</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

